"The fluvoxamine patients reported steady improvements in fatigue and quality-of-life scores over 60 to 90 days, with fewer side effects than a placebo. It also boosted overall quality-of-life scores."
"Metformin, which lowers insulin and blood sugar even in people without diabetes, showed no significant benefit. While all treatments were generally safe, fluvoxamine had fewer reported side effects."
"Professor Christiaan Vinkers from the Amsterdam University Medical Centre said that the study is promising but the pill is unlikely to be a golden bullet."
"'This randomised placebo-controlled trial provides encouraging evidence that fluvoxamine may reduce fatigue in a selected group of patients with long Covid.'"
A clinical trial tested fluvoxamine, metformin, and a placebo on long Covid fatigue in nearly 400 adults. Fluvoxamine showed significant improvements in fatigue and quality of life over 60 to 90 days, with fewer side effects than placebo. Metformin did not demonstrate significant benefits. While all treatments were safe, fluvoxamine emerged as a potential treatment for long Covid fatigue, though its long-term effects remain uncertain. The study did not evaluate participants' depression history, leaving questions about the direct impact on long Covid symptoms.
Read at Mail Online
Unable to calculate read time
Collection
[
|
...
]